21st to 23rd March 2016, Washington, D.C., USA.TAT Congress is a medium-sized annual meeting encompassing 3 days of plenary sessions, poster viewing sessions, special symposia, international faculty and excellent networking opportunities. It is held in Europe (odd years) and the USA (even years). This year the 14th International Congress on Targeted Anticancer Therapies (TAT) takes place in Washington, D.C..

Key characteristics

• Focus at early-phase development and translational research of new cancer drug targets and agents
• Covers targeted agents, immuno-oncology and combinations involving such agents
• Invited lectures by top-level faculty, including phase 1 investigators having hands-on experience
• Highly international participation from over 30 countries across the globe
• Medium-sized meeting offering plenary sessions only
• Excellent networking opportunities in an informal setting
• Offers accredited learning for medical specialists

TAT congresses are of interest to a broad range of professionals, including everyone in the academic environment, industry (pharma, biotech, diagnostic) and drug regulatory agencies, involved in the discovery, development and evaluation of innovative cancer therapeutics. Clinicians working in various fields of medicine, including medical oncology, hematology, immunology, pathology, pharmacology, as well as non-clinicians working in translational cancer research, will find TAT 2016 a very worthwhile event to attend.

Clinicians and scientists conducting clinical and/or translational cancer research are encouraged to take the opportunity to present their work as a proffered paper or poster during te congress. Submit your abstract(s) before the deadline. In past TAT Congress, 80-85% of submitted abstracts were scheduled for presentation, 5-10% as oral papers.

Find the official program here.

Tip: More up to date educational events can be found online in the Education Database »medicine & health«.